基于汇总临床试验数据评估多发性硬化残疾结局指标
多发性硬化结局评估联盟汇总14项临床试验共12776例对照与治疗组患者数据,分析T25FW、9HPT、LCLA、SDMT四项性能指标的心理测量学属性及纵向表现,发现四项指标单独或组合成多维测试电池均可作为研究结局指标,且任一指标进展比EDSS更敏感。
要点
- 四项性能指标重测信度优良,能区分不同病程和EDSS亚组。
- T25FW和9HPT检测3个月确认恶化的进展率低于EDSS,LCLA和SDMT与EDSS相似。
- 任一性能指标进展比EDSS更敏感,且与SF-36 PCS临床意义恶化相关。
核心结论
- 四项性能指标单独或组合成多维测试电池可作为多发性硬化研究结局指标。
研究设计与样本
- 多发性硬化结局评估联盟汇总14项临床试验对照与治疗组共12776例患者标准化数据,分析T25FW、9HPT、LCLA、SDMT的测量属性与纵向表现。
主要发现
- 性能指标重测信度优良,按病程和EDSS水平分组的亚组间差异符合预期。
- 检测3个月确认恶化的进展率:T25FW和9HPT低于EDSS,LCLA和SDMT与EDSS相似。
- 四项指标作为多维测量时,任一性能指标进展比EDSS更敏感。
- 性能指标单独或组合的恶化与SF-36 PCS评分临床意义恶化相关。
临床怎么用
- 可将T25FW、9HPT、LCLA、SDMT单独或组合用于多发性硬化临床试验结局评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We report analyses of a pooled database by the Multiple Sclerosis Outcome Assessments Consortium to evaluate 4 proposed components of a multidimensional test battery. METHODS: Standardized data on 12,776 participants, comprising demographics, multiple sclerosis disease characteristics, Expanded Disability Status Scale (EDSS) score, performance measures, and Short Form-36 Physical Component Summary (SF-36 PCS), were pooled from control and treatment arms of 14 clinical trials. Analyses of Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT), Low Contrast Letter Acuity (LCLA), and Symbol Digit Modalities Test (SDMT) included measurement properties; construct, convergent, and known group validity; and longitudinal performance of the measures individually and when combined into a multidimensional test battery relative to the EDSS and SF-36 to determine sensitivity and clinical meaningfulness. RESULTS: The performance measures had excellent test-retest reliability and showed expected differences between subgroups based on disease duration and EDSS level. Progression rates in detecting time to 3-month confirmed worsening were lower for T25FW and 9HPT compared to EDSS, while progression rates for LCLA and SDMT were similar to EDSS. When the 4 measures were analyzed as a multidimensional measure rather than as individual measures, progression on any one performance measure was more sensitive than the EDSS. Worsening on the performance measures analyzed individually or as a multidimensional test battery was associated with clinically meaningful SF-36 PCS score worsening, supporting clinical meaningfulness of designated performance test score worsening. CONCLUSION: These results support the use of the 4 proposed performance measures, individually or combined into a multidimensional test battery as study outcome measures.
引用
- Goldman MD, LaRocca NG, Rudick RA, et al. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology. 2019. PMID: 31641014. doi:10.1212/WNL.0000000000008519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。